Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia

Blood

Volumn 116, Issue 20, 2010, Pages 4307-4316

  Yang, Lei ^a   Wang, Lin ^a   Zhao, Chun Hong ^b   Zhu, Xiao Juan ^a,c   Hou, Yu ^c   Peng, Jun ^a,d   Hou, Ming ^a,d  

^a SHANDONG UNIVERSITY   (China)

^b YANTAISHAN HOSPITAL   (China)

^c SHANDONG UNIVERSITY   (China)

^d BEIJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; INTERLEUKIN 3; PROTEIN BCL XL; STEM CELL FACTOR; THROMBOPOIETIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; CD34 SELECTION; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MALE; MEGAKARYOCYTE; MONONUCLEAR CELL; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE RELEASE REACTION; THROMBOCYTOPOIESIS; UMBILICAL CORD BLOOD;

EID: 78549239285     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-02-267435     Document Type: Article

References (49)

1. Saleh MN, Moore DL, Lee JY, LoBuglio AF. Monocyte-platelet interaction in immune and nonimmune thrombocytopenia. Blood. 1989;74(4):1328-1331.
2. George JN, el-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1994;331(18):1207-1211.
3. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346(13):995-1008.
4. McMillan R. The pathogenesis of chronic immune (idiopathic) thrombocytopenic purpura. Semin Hematol. 2000;37(1 suppl 1):5-9. (Pubitemid 30080232)
5. Semple JW, Milev Y, Cosgrave D, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood. 1996;87(10):4245-4254. (Pubitemid 26152268)
6. Semple JW, Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood. 1991;78(10):2619-2625.
7. Sakakura M, Wada H, Tawara I, et al. Reduced CD4+CD25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res. 2007;120(2):187-193.
8. Yu J, Heck S, Patel V, et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood. 2008;112(4):1325-1328.
9. Olsson B, Andersson PO, Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9(9):1123-1124.
10. Chow L, Aslam R, Speck ER, et al. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy. Blood. 2010;115(6):1247-1253.
11. Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura: evidence of both impaired platelet production and increased platelet clearance. J Clin Invest. 1987;80(1):33-40.
12. Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102(3):887-895.
13. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103(4):1364-1369. (Pubitemid 38168649)
14. Italiano JE Jr, Lecine P, Shivdasani RA, Hartwig JH. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell Biol. 1999;147(6):1299-1312.
15. Hartwig J, Italiano J Jr. The birth of the platelet. J Thromb Haemost. 2003;1(7):1580-1586.
16. Patel SR, Hartwig JH, Italiano JE Jr. The biogenesis of platelets from megakaryocyte proplatelets. J Clin Invest. 2005;115(12):3348-3354.
17. Zauli G, Vitale M, Falcieri E, et al. In vitro senescence and apoptotic cell death of human megakaryocytes. Blood. 1997;90(6):2234-2243.
18. De Botton S, Sabri S, Daugas E, et al. Platelet formation is the consequence of caspase activation within megakaryocytes. Blood. 2002;100(4):1310-1317. (Pubitemid 34864286)
19. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393.
20. Hou M, Peng J, Shi Y, et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol. 2003;70(6):353-357.
21. Norol F, Vitrat N, Cramer E, et al. Effects of cytokines on platelet production from blood and marrow CD34+ cells. Blood. 1998;91(3):830-843.
22. Tajika K, Nakamura H, Nakayama K, Dan K. Thrombopoietin can influence mature megakaryocytes to undergo further nuclear and cytoplasmic maturation. Exp Hematol. 2000;28(2):203-209. (Pubitemid 30100827)
23. Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood. 1995;85(7):1719-1726.
24. Faulhaber M, Wormann B, Ganser A, Verbeek W. In vitro response of myelodysplastic megakaryocytopoiesis to megakaryocyte growth and development factor (MGDF). Ann Hematol. 2002;81(12):695-700.
25. Hou M, Andersson PO, Stockelberg D, Mellqvist UH, Ridell B, Wadenvik H. Plasma thrombopoietin levels in thrombocytopenic states: implication for a regulatory role of bone marrow megakaryocytes. Br J Haematol. 1998;101(3):420-424.
26. Kappers-Klunne MC, de Haan M, Struijk PC, van Vliet HH. Serum thrombopoietin levels in relation to disease status in patients with immune thrombocytopenic purpura. Br J Haematol. 2001;115(4):1004-1006.
27. Chang M, Suen Y, Meng G, et al. Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: insight into the regulation of platelet production. Blood. 1996;88(9):3354-3362. (Pubitemid 26365569)
28. Vainchenker W, Deschamps JF, Bastin JM, et al. Two monoclonal antiplatelet antibodies as markers of human megakaryocyte maturation: immunofluorescent staining and platelet peroxidase detection in megakaryocyte colonies and in in vivo cells from normal and leukemic patients. Blood. 1982;59(3):514-521.
29. Tsubakio T, Tani P, Curd JG, McMillan R. Complement activation in vitro by antiplatelet antibodies in chronic immune thrombocytopenic purpura. Br J Haematol. 1986;63(2):293-300. (Pubitemid 16085862)
30. Houwerzijl EJ, Blom NR, van der Want JJ, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood. 2004;103(2):500-506.
31. Houwerzijl EJ, Blom NR, van der Want JJ, Vellenga E, de Wolf JT. Megakaryocytic dysfunction in myelodysplastic syndromes and idiopathic thrombocytopenic purpura is in part due to different forms of cell death. Leukemia. 2006;20(11):1937-1942.
32. Bassini A, Pierpaoli S, Falcieri E, et al. Selective modulation of the cyclin B/CDK1 and cyclin D/CDK4 complexes during in vitro human megakaryocyte development. Br J Haematol. 1999;104(4):820-828.
33. Dameshek WME. The megakaryocytes in idiopathic thrombocytopenic purpura, a form of hypersplenism. Blood. 1946;1:27-52.
34. Sun L, Hwang WY, Aw SE. Biological characteristics of megakaryocytes: specific lineage commitment and associated disorders. Int J Biochem Cell Biol. 2006;38(11):1821-1826. (Pubitemid 44425242)
35. Clarke MC, Savill J, Jones DB, Noble BS, Brown SB. Compartmentalized megakaryocyte death generates functional platelets committed to caspase-independent death. J Cell Biol. 2003;160(4):577-587.
36. Shenoy S, Mohanakumar T, Chatila T, et a1. Defective apoptosis in lymphocytes and the role of IL-2 in autoimmune hematologic cytopenias. Clin Immunol. 2001;99(2):266-275. (Pubitemid 33718253)
37. Yoshimura C, Nomura S, Nagahama M, et al. Plasma-soluble Fas (APO-1, CD95) and soluble Fas ligand in immune thrombocytopenic purpura. Eur J Haematol. 2000;64(4):219-224.
38. Matsuyama W, Yamamoto M, Higashimoto I, et al. TNF-related apoptosis-inducing ligand is involved in neutropenia of systemic lupus erythematosus. Blood. 2004;104(1):184-191.
39. Matsumura R, Umemiya K, Kagami M, et al. Expression of TNF-related apoptosis inducing ligand (TRAIL) on infiltrating cells and of TRAIL receptors on salivary glands in patients with Sjogren's syndrome. Clin Exp Rheumatol. 2002;20(6):791-798. (Pubitemid 35446969)
40. Chen S, Fazle Akbar SM, Zhen Z, et al. Analysis of the expression of Fas, FasL and Bcl-2 in the pathogenesis of autoimmune thyroid disorders. Cell Mol Immunol. 2004;1(3):224-228.
41. Zauli G, Secchiero P. The role of the TRAIL/ TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev. 2006;17(4):245-257.
42. Crist SA, Elzey BD, Ludwig AT, et al. Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megakaryocytes and platelets. Exp Hematol. 2004;32(11):1073-1081.
43. Melloni E, Secchiero P, Celeghini C, et al. Functional expression of TRAIL and TRAIL-R2 during human megakaryocytic development. J Cell Physiol. 2005;204(3):975-982.
44. Sedger LM, Katewa A, Pettersen AK, et al. Extreme lymphoproliferative disease and fatal autoimmune thrombocytopenia in FasL- and TRAILdouble deficient mice. Blood. 2010;115(16):3258-3268.
45. Terui Y, Furukawa Y, Kikuchi J, Iwase S, Hatake K, Miura Y. Bcl-x is a regulatory factor of apoptosis and differentiation in megakaryocytic lineage cells. Exp Hematol. 1998;26(3):236-244. (Pubitemid 28106835)
46. Sanz C, Benet I, Richard C, et al. Antiapoptotic protein Bcl-x(L) is up-regulated during megakaryocytic differentiation of CD34(+) progenitors but is absent from senescent megakaryocytes. Exp Hematol. 2001;29(6):728-735. (Pubitemid 32500374)
47. Kaluzhny Y, Yu G, Sun S, et al. BclxL overexpression in megakaryocytes leads to impaired platelet fragmentation. Blood. 2002;100(5):1670-1678.
48. Zhang L, Zhao H, Sun A, et al. Early down-regulation of Bcl-xL expression during megakaryocytic differentiation of thrombopoietin-induced CD34+ bone marrow cells in essential thrombocythemia. Haematologica. 2004;89(10):1199-1206.
49. +T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura. Br J Haematol. 2007;139(4):605-611.